QIMR Berghofer’s world leading research recognised with record federal funding

On August 29, 2019 QIMR Berghofer scientists reported have been awarded almost $16 million in the latest round of federal grant funding to progress their vital research into improving the health of Australians (Press release, QIMR Berghofer Medical Research Institute, AUG 29, 2019, View Source [SID1234539114]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Federal Health Minister Greg Hunt has reported the recipients of Investigator Grants from the National Health and Medical Research Council (NHMRC).

QIMR Berghofer scientists secured nine Investigator Grants to explore a diverse range of research, including genetic risk factors of diseases and disorders, improving cancer outcomes, and the study of infectious diseases.

Professor Nick Martin has been awarded more than $3 million to find the genetic causes of mental health problems and translate those findings to preventative measures, with the hope it will ease the burden on Medicare and the Pharmaceutical Benefits Scheme.

Professor Sarah Medland has received $1.6 million to advance our understanding of psychiatric disorders by studying brain imaging and genetics.

Professor Andreas Suhrbier will use his $2.5 million grant to develop interventions for Zika virus and chikungunya virus.

Professor Mark Smyth has been given the highest grant rating, and secured $2.1 million to find new methods to improve cancer immunotherapy.

Professor Amanda Spurdle has received $2.1 million to improve the diagnosis, prevention, and treatment of hereditary cancer and other diseases.

Professor Penelope Webb has been awarded $1.85 million to study how to improve people’s prospects of surviving cancer.

QIMR Berghofer’s Director and CEO, Professor Frank Gannon, said the Institute’s success in securing limited federal research funds reaffirmed its position as a leader in medical research in the country.

"I’m pleased to see five of the nine awards going to female scientists to lead innovative research projects at the Institute, reaffirming the important role women play at QIMR Berghofer," Professor Gannon said.

"It’s also great to see three of our emerging talents in the field of genetics, Doctor Tracy O’Mara, Doctor Katrina Grasby and Doctor Puya Gharahkhani, awarded Emerging Leadership Grants.

"The funding environment for medical research is becoming more competitive and it’s encouraging that our Institute has done so well to secure the highest funding in the state after the University of Queensland and to be the second most successful Medical Research Institute in the country."

Investigator Grant winners:

Professor Sarah Medland – Advancing our understanding of Psychiatric Disorders through Imaging and Genetics.

Professor Nicholas Martin – Adding value to Medicare/PBS to find the genetic causes of mental health problems and translate this to preventive measures.

Doctor Puya Gharahkhani – Identifying the contribution of phenotypic and genetic risk factors for complex traits, with implication to risk prediction and causal inference.

Doctor Tracy O’Mara – Leveraging genetic data to understand endometrial cancer.

Professor Penelope Webb – Enhancing cancer survivorship.

Doctor Katrina Grasby – Effects of structural, mitochondrial, and X chromosome variants on brain structure.

Professor Andreas Suhrbier – Developing interventions for chikungunya and Zika virus.

Professor Mark Smyth – New methods to improve cancer immunotherapy.

Professor Amanda Spurdle – Improving diagnosis, prevention, and treatment of hereditary cancer and other diseases.

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

On August 29, 2019 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that members of the management team will participate in the following upcoming investor conferences (Press release, Pieris Pharmaceuticals, AUG 29, 2019, View Source [SID1234539113]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 14th Annual Biotech Conference

Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston. The Company will conduct one-on-one meetings with institutional investors at this conference.

Baird 2019 Global Healthcare Conference

Thursday, September 5, 2019 at 2:00PM EDT at the InterContinental New York Barclay Hotel in New York City. A webcast of the Company’s presentation will be available at this link.

H.C. Wainwright 21st Annual Global Investment Conference

Monday, September 9, 2019 at 9:10AM EDT at the Lotte New York Palace Hotel in New York City. A webcast of the Company’s presentation will be available at this link.

LABCORP IS SCHEDULED TO PRSENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

On August 29, 2019 LabCorp (NYSE: LH) reported it will participate at the Morgan Stanley Global Healthcare Conference (Press release, LabCorp, AUG 29, 2019, View Source [SID1234539112]). LabCorp’s presentation is planned for Monday, Sept. 9, 2019 at 9:55 a.m. ET.
A live audio webcast will be available via the Company website at www.LabCorp.com and archived for replay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kyowa Kirin Announces an Partial Change Approval Application of FENTOS®TAPE (Code: HFT-290) Submission by Hisamitsu Pharmaceutical in Japan

On August 29, 2019 Kyowa Kirin Co., Ltd., (Kyowa Kirin, President and CEO: Masashi Miyamoto) reported that Hisamitsu Pharmaceutical Co., Inc. (Hisamitsu Pharmaceutical, President and CEO: Kazuhide Nakatomi) has submitted a new drug application for the additional indications of opioid analgesic naïve cancer pain relief for the transdermal, pain management patch FENTOSTAPE (Development code: HFT-290, generic name: fentanyl citrate, "the product") in Japan (Press release, Kyowa Hakko Kirin, AUG 29, 2019, View Source [SID1234539111]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hisamitsu Pharmaceutical has conducted the clinical study in opioid analgesic naïve cancer pain patients with the product (starting dose at 0.5mg) and confirmed the efficacy and safety of the product.

The product was granted the approval for the treatment of pain relief in various cancers that accompany moderate to severe pain in April 2010 and the additional indication approval for chronic pain in June 2014. In addition, the product was granted the additional approval of a new dose of 0.5mg in July 2018.

Kyowa Kirin and Hisamitsu Pharmaceutical have jointly carried out product distribution and activities of the provision and collection of information (1 brand, 2 channels) since June 2010. Through providing appropriate information of the product with Hisamitsu Pharmaceutical, Kyowa Kirin looks forward to giving further contribution to improve quality of life in patients suffering from cancer pain or chronic pain.

Hisamitsu Pharmaceutical expects to receive a manufacturing and marketing approval of the additional indications by February 2021.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Kura Oncology to Participate in Two Upcoming Investor Conferences

On August 29, 2019 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences (Press release, Kura Oncology, AUG 29, 2019, View Source [SID1234539110]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A panel discussion entitled "Focusing the Laser on Precision Oncology" at Citi’s 14th Annual Biotech Conference in Boston at 9:30 a.m. ET / 6:30 a.m. PT on September 5, 2019; and

An analyst-led discussion at H.C. Wainwright 21st Annual Global Investment Conference in New York at 12:50 p.m. ET / 9:50 a.m. PT on September 10, 2019.
A live audio webcast of both discussions will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available immediately following the event.